
Opinion|Videos|October 28, 2024
Treatment Considerations for PSMA-Positive mCRPC Patients
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Kevin Zorn, MD, on selecting among different MIST options for BPH
5







